- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, today announced the appointment of Louis Scotti to the newly created position of Chief Business Development Officer. Mr. Scotti will be responsible for all business development activities and managing the company's numerous existing collaborations for its NanoActive™ technology platform, which significantly improves the solubility, permeability and pharmacokinetics of diverse chemical and biological compounds.
"We are pleased that Mr. Scotti has joined our senior management team at DRGT," said Gabor Heltovics, CEO of DRGT. "With his long track record of concluding major drug development collaborations with pharmaceutical and biotechnology companies worldwide, Mr. Scotti will be an integral part of our efforts to expand the successful application of our proprietary technologies."
Mr. Scotti most recently served in senior commercial roles during a 12-year career at Arena Pharmaceuticals, Inc., a NASDAQ listed company that recently received FDA approval of Belviq® (lorcaserin HCl), the first prescription weight-loss treatment approved by FDA in 13 years. At Arena, Mr. Scotti held several positions, including Vice President Business Development, Vice President Marketing & Business Development and Vice President Commercial Planning. He was directly responsible for corporate alliances with major pharmaceutical companies such as Merck, J&J and Eli Lilly. Previously, Mr. Scotti was CEO of ProtoMed, Inc. and earlier headed licensing activities as executive director for Ligand Pharmaceuticals, Inc. Mr. Scotti holds a B.S.E. in biomedical engineering from the University of Pennsylvania.
About Druggability Technologies Holdings Limited (DRGT)
Headquartered in Dublin, Ireland, DRGT, through its subsidiaries, is developing and commercializing its proprietary NanoActive™ high throughput technology platform. This platform delivers significant improvements in compound solubility, permeability and pharmacokinetics that can be applied across a diverse universe of chemical and biological compounds.
The Company's experience in improving the bioavailability and kinetic profile of drugs is born of a heritage of three decades of scientific and industrial knowledge gained through successful commercial ventures in bio- and chemo-informatics, combinatorial chemistry, chemical genomics, flow chemistry, colloidal chemistry, and nanotechnology.
For more information, please click here
Druggability Technologies Holdings Ltd.
Chief Executive Officer
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information